Cancer Care Updates ‘Helping Hand’ Guide

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 5
Volume 7
Issue 5

NEW YORK--Cancer Care, Inc. has just released the second edition of A Helping Hand: The Resource Guide for People with Cancer, with support from Zeneca Pharmaceuticals. The handbook is designed to show newly diagnosed cancer patients the kind of help that is available and where it can be found.

NEW YORK--Cancer Care, Inc. has just released the second edition of A Helping Hand: The Resource Guide for People with Cancer, with support from Zeneca Pharmaceuticals. The handbook is designed to show newly diagnosed cancer patients the kind of help that is available and where it can be found.

The second edition has updated listings, new sections (for example, on how to use the Internet to find information), and a wealth of information on national, regional, and local cancer-related organizations that provide critically important services for people with cancer.

Cancer Care, Inc. is the largest agency in the nation dedicated solely to providing support for cancer patients and their families and friends, as well as education for the general public. The first copy of the resource guide is available free of charge through the agency’s toll-free counseling line at 1-800-813-HOPE (4673) or through a Zeneca sales rep.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content